MY177326A - Pyrazole compounds as sglt1 inhibitors - Google Patents

Pyrazole compounds as sglt1 inhibitors

Info

Publication number
MY177326A
MY177326A MYPI2014703279A MYPI2014703279A MY177326A MY 177326 A MY177326 A MY 177326A MY PI2014703279 A MYPI2014703279 A MY PI2014703279A MY PI2014703279 A MYPI2014703279 A MY PI2014703279A MY 177326 A MY177326 A MY 177326A
Authority
MY
Malaysia
Prior art keywords
pyrazole compounds
sglt1 inhibitors
sglt1
inhibitors
pyrazole
Prior art date
Application number
MYPI2014703279A
Other languages
English (en)
Inventor
Qu Fucheng
Bryan Mantlo Nathan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY177326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY177326A publication Critical patent/MY177326A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2014703279A 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors MY177326A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26

Publications (1)

Publication Number Publication Date
MY177326A true MY177326A (en) 2020-09-11

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014703279A MY177326A (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors

Country Status (42)

Country Link
US (2) US8697849B2 (enExample)
EP (1) EP2850084B1 (enExample)
JP (1) JP6148725B2 (enExample)
KR (1) KR101685779B1 (enExample)
AP (1) AP3593A (enExample)
AR (1) AR090806A1 (enExample)
AU (1) AU2013259946B2 (enExample)
BR (1) BR112014026198B1 (enExample)
CA (1) CA2869323C (enExample)
CL (1) CL2014002845A1 (enExample)
CO (1) CO7141429A2 (enExample)
CR (1) CR20140473A (enExample)
CY (1) CY1117912T1 (enExample)
DK (1) DK2850084T3 (enExample)
DO (1) DOP2014000250A (enExample)
EA (1) EA024207B1 (enExample)
EC (1) ECSP14026088A (enExample)
ES (1) ES2588835T3 (enExample)
GT (1) GT201400242A (enExample)
HR (1) HRP20160804T1 (enExample)
HU (1) HUE030414T2 (enExample)
IL (1) IL235427A (enExample)
IN (1) IN2014DN07996A (enExample)
JO (1) JO3136B1 (enExample)
LT (1) LT2850084T (enExample)
MA (1) MA37501B1 (enExample)
ME (1) ME02405B (enExample)
MX (1) MX357058B (enExample)
MY (1) MY177326A (enExample)
NZ (1) NZ700356A (enExample)
PE (1) PE20142399A1 (enExample)
PH (1) PH12014502492A1 (enExample)
PL (1) PL2850084T3 (enExample)
PT (1) PT2850084T (enExample)
RS (1) RS55107B1 (enExample)
SG (1) SG11201407345QA (enExample)
SI (1) SI2850084T1 (enExample)
TN (1) TN2014000410A1 (enExample)
TW (1) TWI579295B (enExample)
UA (1) UA113086C2 (enExample)
WO (1) WO2013169546A1 (enExample)
ZA (1) ZA201407531B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
AR098134A1 (es) 2013-11-01 2016-05-04 Lilly Co Eli Compuestos de urea
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
TWI805727B (zh) * 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213296B1 (en) 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
BRPI0313290B1 (pt) * 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
RU2437876C2 (ru) * 2006-05-19 2011-12-27 Тайсо Фармасьютикал Ко., Лтд. Соединение с-фенилглицитола для лечения диабета
ES2548578T3 (es) 2007-12-27 2015-10-19 Kissei Pharmaceutical Co., Ltd. Monosebacato de un derivado de pirazol
PE20120648A1 (es) 2009-02-23 2012-05-31 Taisho Pharmaceutical Co Ltd Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
WO2013169546A1 (en) 2013-11-14
JP2015516419A (ja) 2015-06-11
HRP20160804T1 (hr) 2016-08-12
DK2850084T3 (en) 2016-09-12
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
TW201406773A (zh) 2014-02-16
ME02405B (me) 2016-09-20
EP2850084B1 (en) 2016-06-15
GT201400242A (es) 2015-08-27
AU2013259946B2 (en) 2015-09-10
AP2014008044A0 (en) 2014-11-30
MA37501B1 (fr) 2016-11-30
EP2850084A1 (en) 2015-03-25
CY1117912T1 (el) 2017-05-17
PL2850084T3 (pl) 2017-05-31
MX357058B (es) 2018-06-25
CN104284894A (zh) 2015-01-14
JP6148725B2 (ja) 2017-06-14
JO3136B1 (ar) 2017-09-20
PH12014502492B1 (en) 2015-01-12
CL2014002845A1 (es) 2015-01-30
AR090806A1 (es) 2014-12-10
ZA201407531B (en) 2016-05-25
PT2850084T (pt) 2016-08-02
US20130303471A1 (en) 2013-11-14
LT2850084T (lt) 2016-09-12
EA201491852A1 (ru) 2015-02-27
NZ700356A (en) 2016-06-24
CR20140473A (es) 2014-11-21
HUE030414T2 (en) 2017-05-29
EA024207B1 (ru) 2016-08-31
IL235427A (en) 2016-06-30
TWI579295B (zh) 2017-04-21
CA2869323C (en) 2016-03-29
US9296775B2 (en) 2016-03-29
SG11201407345QA (en) 2014-12-30
CO7141429A2 (es) 2014-12-12
KR20150001798A (ko) 2015-01-06
PH12014502492A1 (en) 2015-01-12
ECSP14026088A (es) 2015-09-30
PE20142399A1 (es) 2015-01-22
US20140162967A1 (en) 2014-06-12
SI2850084T1 (sl) 2016-07-29
CA2869323A1 (en) 2013-11-14
TN2014000410A1 (en) 2015-12-21
IN2014DN07996A (enExample) 2015-05-01
CN104284894B (zh) 2016-02-17
US8697849B2 (en) 2014-04-15
BR112014026198A2 (pt) 2017-06-27
RS55107B1 (sr) 2016-12-30
HK1202542A1 (zh) 2015-10-02
AP3593A (en) 2016-02-15
BR112014026198B1 (pt) 2021-02-02
MA37501A1 (fr) 2016-03-31
AU2013259946A1 (en) 2014-10-16
DOP2014000250A (es) 2014-11-30
ES2588835T3 (es) 2016-11-07
MX2014013615A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
IN2015DN00598A (enExample)
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
PH12016500169A1 (en) Polymorph of syk inhibitors
MX361499B (es) Baricitinib deuterado.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MX2015012629A (es) Compuestos de imidazo piridina.
MY184303A (en) Notch pathway signaling inhibitor compound
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
JO3318B1 (ar) مثبطات bace
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
IN2014CN04449A (enExample)
MX364207B (es) Inhibidores de agrecanasa.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2016007985A (es) Compuestos de fluorofenilpirazol.
GB201020397D0 (en) Compounds
PH12016500809A1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
TN2013000515A1 (en) Notch pathway signaling inhibitor compound